RYAN'S QUEST

PO BOX 2544 

HAMILTON, NJ 08690

© 2019 Ryan's Quest       501(c) (3)Documentation

(609) 947-3611

August 3, 2015

Hamilton, New Jersey, August 3, 2015—The Ryan’s Quest Foundation, a non-profit organization specific to Duchenne muscular dystrophy, announced today the award of their most recent contribution toward the fight to end Duchenne muscular dystrophy. The Foundation has awarded ReveraGen BioPharma $50,000 towards a clinical trial for a potential steroid alternative. The grant was facilitated through a newly formed partnership of Duc...

June 18, 2015

 

Interim Clinical Data from Ongoing Phase 1b/2a Clinical Program Highlights Statistically Significant Improvements in Muscle Strength

 

Cambridge, Mass. - June 18 , 2015 - Akashi Therapeutics Inc., a clinical stage biopharmaceutical company developing treatments for Duchenne muscular dystrophy (DMD), today announced positive interim clinical data from an ongoing Phase 1b/2a clinical program with HT-100 (delayed-release halofugin...

April 9, 2015

Cleveland and Columbus, OH, April 9, 2015—Milo Biotechnology announced the first Duchenne muscular dystrophy (DMD) patient was treated with follistatin gene therapy at Nationwide Children’s Hospital. The therapy, delivered by intramuscular injection, is designed to maintain or restore muscle function in boys affected with DMD. This six patient clinical trial follows from a trial of the therapy in Becker muscular dystrophy pati...

Please reload

Please reload

Recent Posts
Search By Tags